VISCHER advised Versameb in its CHF 6 million seed financing round

Versameb, a preclinical-stage biopharmaceutical company located in Basel, has closed a CHF 6 million seed financing round. Versameb is engaged in the discovery and development of next-generation RNA-based drugs using its proprietary VERSagile technology platform developing molecules targeting regulation of immune response or regeneration in the fields of dermatology, oncology and myology.

The advisor

VISCHER advises Versameb in this transaction. The team included partner Matthias Staehelin (pictured), managing associates Moritz Jäggy and Dania Salvisberg-Schneider (all Corporate).